Twist Bioscience to acquire Abveris for up to $190M in stock and cash

Twist Bioscience Corp

Total consideration up to $190M: $150M at close (Twist stock + up to $10M cash) plus up to $40M stock tied to 2022 revenue target.
Stock price per share collared between $106.10 and $129.68 based on 30-day VWAP before closing.
Abveris adds in vivo antibody discovery platform (DiversimAb mice) to complement Twist's synthetic library and AI capabilities.
Acquisition expected to bolster Twist's biopharma antibody design, discovery, and screening services for partners and internal pipeline.
Deal structured as a merger; shares issued in private placement exempt from registration under Section 4(a)(2) and Rule 506.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.